A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)
Status:
Completed
Trial end date:
2017-01-18
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety and tolerability of 2 dose levels of
MK-0653H in Japanese participants. The primary hypotheses are that the administration of
MK-0653H is safe and tolerable and that MK-0653H is superior to single entity of Ezetimibe
and Rosuvastatin in percent reduction from baseline in low-density lipoprotein-cholesterol
(LDL-C) after 12 weeks of treatment.